SEATTLE and SOUTH SAN FRANCISCO, Calif., April 15, 2015 (GLOBE NEWSWIRE) -- Immune Design (Nasdaq:IMDZ) today announced the pricing of an underwritten public offering of 3,000,000 shares of its common stock at a price to the public of $26.50 per share for total gross proceeds of approximately $79.5 million, before deducting underwriting discounts and commissions and estimated expenses. All of the shares of common stock are being offered by Immune Design. In addition, Immune Design has granted the underwriters a 30-day option to purchase up to 450,000 additional shares of common stock at the offering price, less underwriting discounts and commissions. The offering is expected to close on April 21, 2015, subject to customary closing conditions.
Jefferies LLC, Leerink Partners LLC and Cowen and Company, LLC are acting as joint book-running managers, and Wells Fargo Securities, LLC is acting as lead manager for the offering.
A registration statement relating to the common stock being offered by Immune Design was declared effective by the Securities and Exchange Commission on April 15, 2015. The offering is being made only by means of a final prospectus, which is part of the effective registration statement. Copies of the final prospectus, when available, may be obtained by contacting Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, telephone: (877) 547-6340, e-mail: Prospectus_Department@Jefferies.com; Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at (800) 808-7525 ext. 6142, or by email at syndicate@leerink.com; or Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY, 11717, Attention: Prospectus Department, telephone: (631) 274-2806, fax: (631) 254-7140.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Immune Design
Immune Design is a clinical-stage immunotherapy company employing next-generation in vivo approaches to enable the body's immune system to fight disease. The company's technologies are engineered to activate the immune system's natural ability to generate and/or expand antigen-specific cytotoxic T cells, while enhancing other immune effectors, to fight cancer and other chronic diseases. CMB305 and G100, the two-pronged focus of Immune Design's ongoing immuno-oncology clinical programs, are the product of its two synergistic discovery platforms: ZVex and GLAAS. Immune Design has offices in Seattle and South San Francisco.